CEL-SCI Corp CVM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
CEL-SCI Announces Closing of Offering
-
CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy
-
CEL-SCI Corporation Announces Pricing of Offering
-
CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia
-
CEL-SCI Reports Fiscal Second Quarter 2026 Results
-
CEL-SCI Announces Closing of Public Offering
-
CEL-SCI Corporation Announces Pricing of Public Offering
-
CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia
Trading Information
- Previous Close Price
- $1.01
- Day Range
- $1.00–1.14
- 52-Week Range
- $0.89–13.48
- Bid/Ask
- $1.04 / $1.14
- Shares Outstanding
- 14.49M
- Market Cap
- $19.22M
- Volume/Avg
- 684,504 / 380,071
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 44
- Website
- https://www.cel-sci.com
Valuation
|
Metric
|
CVM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.33 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CVM
|
|---|---|
Quick Ratio | 0.39 |
Current Ratio | 0.60 |
Interest Coverage | −43.88 |
Quick Ratio
CVM
Profitability
|
Metric
|
CVM
|
|---|---|
Return on Assets (Normalized) | −93.14% |
Return on Equity (Normalized) | −210.83% |
Return on Invested Capital (Normalized) | −104.43% |
Return on Assets
CVM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Affymax Inc
AFFY
| — | Zjqmj | — | |||
| Athersys Inc
ATHXQ
| — | Zlymd | — | |||
| Vertex Pharmaceuticals Inc
VRTX
| Lyrlmsqml | Nwktbfn | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Yrnncdxw | Pxpmbr | $64B | |||
| UCB SA
UCBJF
| — | Dtppb | $61B | |||
| UCB SA ADR
UCBJY
| — | Fzny | $61B | |||
| argenx SE
ARGNF
| — | Nczq | $56B | |||
| argenx SE ADR
ARGX
| Mgxhjyrxq | Xlff | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Cpyrccf | Scqdnv | $38B | |||
| CSL Ltd
CMXHF
| — | Zhmnzl | $36B |
United States